Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:NVAX NASDAQ:XOMA NASDAQ:XOMAO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$22.08-1.3%$22.29$14.40▼$47.00$1.49B1.221.47 million shs1.33 million shsNVAXNovavax$7.47-1.5%$7.40$5.01▼$15.22$1.23B2.59.39 million shs6.39 million shsXOMAXOMA Royalty$32.47-0.7%$28.10$18.35▼$35.22$395.27M156,471 shs30,661 shsXOMAOXOMA$25.40+0.1%$25.44$23.32▼$25.87N/AN/A2,942 shs1,165 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-1.34%-1.69%-3.20%+13.29%-42.60%NVAXNovavax-1.45%-4.72%+9.05%+1.08%-32.88%XOMAXOMA Royalty-0.70%-5.06%+26.59%+31.83%+11.97%XOMAOXOMA-0.12%+0.04%-0.82%+0.44%-0.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.8394 of 5 stars3.43.00.00.02.80.00.0NVAXNovavax4.4714 of 5 stars3.12.00.04.72.00.83.1XOMAXOMA Royalty4.1354 of 5 stars3.34.00.03.02.71.70.6XOMAOXOMAN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.78Moderate Buy$46.67111.35% UpsideNVAXNovavax 2.13Hold$14.2991.24% UpsideXOMAXOMA Royalty 2.67Moderate Buy$69.50114.04% UpsideXOMAOXOMA 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest XOMA, XOMAO, CLDX, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.008/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $42.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.008/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M208.88N/AN/A$9.87 per share2.24NVAXNovavax$682.16M1.78N/AN/A$0.23 per share32.48XOMAXOMA Royalty$28.49M13.78N/AN/A$5.99 per share5.42XOMAOXOMA$12.77MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)NVAXNovavax-$187.50M$2.283.2893.380.1039.20%-142.33%28.65%11/11/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)XOMAOXOMAN/AN/A0.00∞N/AN/AN/AN/A11/5/2025 (Estimated)Latest XOMA, XOMAO, CLDX, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/AXOMAOXOMA$2.098.23%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A19.6719.67NVAXNovavax5.932.362.34XOMAXOMA Royalty1.414.884.88XOMAOXOMAN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/ANVAXNovavax53.04%XOMAXOMA Royalty95.92%XOMAOXOMAN/AInsider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%NVAXNovavax1.00%XOMAXOMA Royalty9.10%XOMAOXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionableXOMAOXOMA10N/AN/ANot OptionableXOMA, XOMAO, CLDX, and NVAX HeadlinesRecent News About These CompaniesShort Interest in XOMA Co. (NASDAQ:XOMAO) Decreases By 23.1%August 22, 2025 | americanbankingnews.comMural Oncology accepts XOMA takeover bidAugust 21, 2025 | thepharmaletter.comTMural Jumps on Partnership with XOMAAugust 20, 2025 | baystreet.caMural Oncology To Be Acquired By Xoma RoyaltyAugust 20, 2025 | msn.comXOMA Royalty to Buy Mural Oncology for Up to $38.8 MillionAugust 20, 2025 | marketwatch.comXoma adds fading Mural Oncology to portfolio of struggling biotechsAugust 20, 2025 | fiercebiotech.comFXoma reports Q2 EPS 44c, consensus (15c)August 13, 2025 | msn.comXOMA Revenue Jumps 39% in Fiscal Q2August 13, 2025 | aol.comAXOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business AchievementsAugust 13, 2025 | finance.yahoo.comPharmalittle: We’re reading about Bill Gates’ women’s health pledge, a Vertex pain drug failure, and moreAugust 5, 2025 | statnews.comSPromise of gamma delta bispecific antibodies prompts XOMA acquisitionAugust 5, 2025 | thepharmaletter.comTXoma Royalty to Acquire Lava TherapeuticsAugust 4, 2025 | marketwatch.comHillevax Shares Gain on Acquisition Deal with XOMA RoyaltyAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics, End Development of Lead CandidateAugust 4, 2025 | precisionmedicineonline.comPXoma strikes deals to buy struggling biotechs HilleVax, LavaAugust 4, 2025 | finance.yahoo.comXoma Royalty to Acquire HilleVaxAugust 4, 2025 | marketwatch.comXOMA Royalty to acquire cancer drug developer LAVA TherapeuticsAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics -- UpdateAugust 4, 2025 | marketwatch.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? - NasdaqJune 26, 2025 | nasdaq.comWhy XOMA Royalty Corporation’s (XOMA) Stock Is Down 5.18%May 1, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMA, XOMAO, CLDX, and NVAX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$22.08 -0.30 (-1.34%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$22.08 0.00 (0.00%) As of 08/29/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Novavax NASDAQ:NVAX$7.47 -0.11 (-1.45%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.48 +0.01 (+0.13%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.XOMA Royalty NASDAQ:XOMA$32.47 -0.23 (-0.70%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$32.44 -0.03 (-0.11%) As of 08/29/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.XOMA NASDAQ:XOMAO$25.40 +0.04 (+0.14%) Closing price 08/29/2025 03:55 PM EasternExtended Trading$25.33 -0.07 (-0.27%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
